In a prospective study, a UK research group investigated the need for insulin treatment among T2D patients and found that 84–94% of DMab-positive patients needed insulin 6 years after diagnosis, compared with only 14% of DMab-negative patients [30]. Here, INS is linked to type 2 diabetes mellitus.